Baricitinib: First Systemic Oral Drug for Alopecia Therapy

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MISHRA PRASHANT; Sinha Sharmila; Vihan Sandeep; Dahiya Navdeep; Vasudevan Biju

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF PHARMACEUTICAL CARE Year:2022 | Volume:10 | Issue:3 Page(s): 167-173

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Baricitinib: First Systemic Oral Drug for Alopecia Therapy

Author(s)

Keywords

Alopecia

Baricitinib

Hair Follicle

Janus Kinase Inhibitors

Abstract

Baricitinib, a Janus kinase inhibitor, was originally approved as anti-rheumatic drug in 2017. In 2020, it was approved for the treatment of COVID-19 in selected hospitalized adults. Baricitinib received priority review designation for treatment of adult patients with severe Alopecia areata and got USFDA approval on June 23, 2022 based on the results of 02 phase III trial: BRAVE-AA1 and BRAVE-AA2. In this review, we aim to summarize the different pharmacokinetic and pharmacodynamics aspects including drug interactions, adverse effects/black box warnings and their clinical relevance. We reiterate that oral JAK inhibitors are expensive, may carry significant risks, and are not yet recommended for routine treatment of Alopecia areata. There is ongoing research on other topical and oral JAK inhibitors (tofacitinib and ruxolitinib), giving hope that better treatments for Alopecia areata will become available in future.

Cites

No record.

References

Cite

APA: Copy

MISHRA, PRASHANT, Sinha, Sharmila, Vihan, Sandeep, Dahiya, Navdeep, & Vasudevan, Biju. (2022). Baricitinib: First Systemic Oral Drug for Alopecia Therapy. JOURNAL OF PHARMACEUTICAL CARE, 10(3), 167-173. SID. https://sid.ir/paper/1007127/en

Vancouver: Copy

MISHRA PRASHANT, Sinha Sharmila, Vihan Sandeep, Dahiya Navdeep, Vasudevan Biju. Baricitinib: First Systemic Oral Drug for Alopecia Therapy. JOURNAL OF PHARMACEUTICAL CARE[Internet]. 2022;10(3):167-173. Available from: https://sid.ir/paper/1007127/en

IEEE: Copy

PRASHANT MISHRA, Sharmila Sinha, Sandeep Vihan, Navdeep Dahiya, and Biju Vasudevan, “Baricitinib: First Systemic Oral Drug for Alopecia Therapy,” JOURNAL OF PHARMACEUTICAL CARE, vol. 10, no. 3, pp. 167–173, 2022, [Online]. Available: https://sid.ir/paper/1007127/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops